Exploration of the relationship between cumulative exposure to tobramycin and ototoxicity in patients with cystic fibrosis
Journal of Cystic Fibrosis · 2023
DOI: 10.1016/j.jcf.2023.04.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2023. Verfasst von Justine Madaule und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacokinetics and Toxicology Laboratory, Toulouse University Hospital, France. Hauptthemen laut MEDLINE: Cystic Fibrosis, Ototoxicity, Hearing Loss. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Aminoglycosides (AGs), such as tobramycin, are essential antibiotics in the management of pulmonary infections in patients with cystic fibrosis (CF). They induce ototoxicity without the relationship being clearly described in the literature. Our aim is to propose a mathematical and statistical model describing the relationship between the estimated cumulative exposure (Area Under the Curve, AUC) to tobramycin and ototoxicity with audiogram interpretation in young patients with CF. METHODS: Cumulative AUCs were estimated for each course of tobramycin, for the 106 individuals with CF (between 4 and 22 years of age) enrolled in this retrospective study (35 who had received IV tobramycin, 71 controls). Mean hearing loss was calculated for each audiogram and a statistical model was developed to predict hearing loss. RESULTS: The model confirms a significant relationship between cumulative tobramycin exposure and changes in hearing acuity: Meanhearingloss=2.7+(3×10-5)×AUC_tobramycin+individual_susceptibility However, the ototoxic effect is not clinically perceptible (mean hearing loss: 3.8 dB). The impact of AUC on hearing loss is minor in these subjects who received a limited number of courses of tobramycin (median: 5 courses). CONCLUSION: A significant relationship between cumulative exposure to tobramycin and ototoxicity was demonstrated. Individual treatment susceptibility should not be overlooked. As ototoxicity is not clinically perceptible in the study subjects, hearing tests should be continued during adulthood to provide individualized medical guidance and to obtain a lifetime analysis of the relationship between exposure and hearing loss.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacokinetics and Toxicology Laboratory, Toulouse University Hospital, France.
- ENT, Otoneurology and Paediatric ENT, Toulouse University Hospital, France.
- Paediatrics - Pulmonology and Allergology, Toulouse University Hospital, France; Cystic Fibrosis Resources and Competence Centre, Toulouse University Hospital, France.
- ENT, Otoneurology and Paediatric ENT, Toulouse University Hospital, France; Cystic Fibrosis Resources and Competence Centre, Toulouse University Hospital, France.
- Adult Cystic Fibrosis Center, Pulmonology, CHU Toulouse, France.
- INTHERES (Therapeutic Innovation and Resistance), Toulouse University, INRAE (French National Research Institute for Agriculture, Food and Environment), ENVT (National Veterinary School of Toulouse), France.
Zitieren
APA
Madaule, J., Valenzuela, F., Mittaine, M., Gallois, Y., Baladi, B., Murris, M., Calmels, M. N., Concordet, D., & Gandia, P. (2023). Exploration of the relationship between cumulative exposure to tobramycin and ototoxicity in patients with cystic fibrosis. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2023.04.002
Vancouver
Madaule J, Valenzuela F, Mittaine M, Gallois Y, Baladi B, Murris M, et al. Exploration of the relationship between cumulative exposure to tobramycin and ototoxicity in patients with cystic fibrosis. Journal of Cystic Fibrosis. 2023. doi:10.1016/j.jcf.2023.04.002
BibTeX
@article{Madaule2023,
author = {Madaule, Justine and Valenzuela, Félix and Mittaine, Marie and Gallois, Yohan and Baladi, Blandine and Murris, Marlène and Calmels, Marie-Noelle and Concordet, Didier and Gandia, Peggy},
title = {Exploration of the relationship between cumulative exposure to tobramycin and ototoxicity in patients with cystic fibrosis},
journal = {Journal of Cystic Fibrosis},
year = {2023},
doi = {10.1016/j.jcf.2023.04.002}
}
EUVIMED